Genital Herpes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Genital Herpes Pipeline Drugs Market Overview
Genital Herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused by the herpes simplex virus (HSV). Symptoms include decreased appetite, fever, general sick feeling (malaise), muscle aches in the lower back, buttocks, thighs, or knees and swollen and tender lymph nodes in the groin during an outbreak. Treatment includes antiviral medications.
The Genital Herpes – drugs in development research report provides a comprehensive overview on the therapeutics under development for Genital Herpes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Genital herpes and features dormant and discontinued projects.
Key Targets | DNA, DNA Helicase, DNA Primase, Envelope Glycoprotein D, Lipopolysaccharide, and Matrix Metalloproteinase 9 |
Key Mechanisms of action | DNA Helicase Inhibitor, DNA Primase Inhibitor, DNA Synthesis Inhibitor, Lipopolysaccharide Inhibitor, and Matrix Metalloproteinase 9 Inhibitor |
Key Routes of Administration | Topical, Oral, Intramuscular, Vaginal, Nasal, Intradermal, Ophthalmic, and Subcutaneous |
Key Molecule Types | Small Molecule, Live Attenuated Vaccine, DNA Vaccine, Recombinant Vector Vaccine, Synthetic Peptide, mRNA Vaccine, Subunit Vaccine, Monoclonal Antibody, and Vaccine |
Major companies | Rational Vaccines Inc, AiCuris Anti-infective Cures AG, NanoViricides Inc, Shulov Innovative Science Ltd, Abivax SA, AlphaVax Inc, Anteris Technologies Ltd, Astellas Pharma Inc, Auritec Pharmaceuticals Inc, Auro Vaccines LLC, and Biomere LLC |
Key Targets in the Genital Herpes Pipeline Drugs Market
The key targets in the Genital Herpes pipeline drugs market are DNA, DNA Helicase, DNA Primase, Envelope Glycoprotein D, Lipopolysaccharide, and Matrix Metalloproteinase 9.
Genital Herpes Drugs Market, by Targets, 2021 (%)
For more target insights, download a free report sample
Key MoA in the Genital Herpes Pipeline Drugs Market
The key mechanisms of action in the Genital Herpes Pipeline drugs market are DNA Helicase Inhibitor, DNA Primase Inhibitor, DNA Synthesis Inhibitor, Lipopolysaccharide Inhibitor, and Matrix Metalloproteinase 9 Inhibitor.
Genital Herpes Pipeline Drugs Market, by MoA, 2021 (%)
To get more insights on key MoA, download a free sample report
Genital Herpes Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Genital Herpes Pipeline drugs market are Topical, Oral, Intramuscular, Vaginal, Nasal, Intradermal, Ophthalmic, and Subcutaneous.
Genital Herpes Pipeline Drugs Market Analysis, by RoA, 2021 (%)
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Genital Herpes Pipeline Drugs Market
The key molecule types in the Genital Herpes Pipeline drugs market are Small Molecule, Live Attenuated Vaccine, DNA Vaccine, Recombinant Vector Vaccine, Synthetic Peptide, mRNA Vaccine, Subunit Vaccine, Monoclonal Antibody, and Vaccine.
Genital Herpes Pipeline Drugs Market, by Molecule Type, 2021 (%)
To get more insights on key molecule types, download a free sample report
Major Companies in the Genital Herpes Pipeline Drugs Market
The major companies in the Genital Herpes Pipeline drugs market are Rational Vaccines Inc, AiCuris Anti-infective Cures AG, NanoViricides Inc, Shulov Innovative Science Ltd, Abivax SA, AlphaVax Inc, Anteris Technologies Ltd, Astellas Pharma Inc, Auritec Pharmaceuticals Inc, Auro Vaccines LLC, and Biomere LLC among others.
Rational Vaccines Inc: Abivax SA (Abivax) operates as a biotechnology company. It develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious and viral diseases. The company’s pipeline products include ABX464, ABX544 and ABX196. Its ABX464 is an oral small molecule to induce functional cure in HIV-patients and inflammatory bowel diseases caused by a dysregulated immune response to host intestinal microflora.
Genital Herpes Pipeline Drugs Market, by Major Companies, 2021 (%)
For more company insights, download a free sample report
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Herpes
- The pipeline guide reviews pipeline therapeutics for Genital Herpes by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Genital Herpes therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Genital Herpes therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Genital Herpes
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Genital Herpes
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Genital Herpes Pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
AiCuris Anti-infective Cures AG
AlphaVax Inc
Anteris Technologies Ltd
Astellas Pharma Inc
Auritec Pharmaceuticals Inc
Auro Vaccines LLC
Biomere LLC
BioNTech SE
BlueWillow Biologics Inc
Brandenburg Antiinfektiva GmbH
GlaxoSmithKline Plc
iosBio Pharma Ltd
NanoViricides Inc
Nykode Therapeutics AS
Rational Vaccines Inc
Sanofi
Shulov Innovative Science Ltd
SL VaxiGen Inc
Starpharma Holdings Ltd
United BioPharma Inc
Vaxart Inc
Vir Biotechnology Inc
Vironova Medical AB
Wuhan Binhui Biotechnology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Genital Herpes Pipeline drugs market?
The key targets in the Genital Herpes Pipeline drugs market are DNA, DNA Helicase, DNA Primase, Envelope Glycoprotein D, Lipopolysaccharide, and Matrix Metalloproteinase 9.
-
What are the key mechanisms of action in the Genital Herpes Pipeline drugs market?
The key mechanisms of action in the Genital Herpes Pipeline drugs market are DNA Helicase Inhibitor, DNA Primase Inhibitor, DNA Synthesis Inhibitor, Lipopolysaccharide Inhibitor, and Matrix Metalloproteinase 9 Inhibitor.
-
What are the key routes of administration in the Genital Herpes Pipeline drugs market?
The key routes of administration in the Genital Herpes Pipeline drugs market are Topical, Oral, Intramuscular, Vaginal, Nasal, Intradermal, Ophthalmic, and Subcutaneous.
-
What are the key molecule types in the Genital Herpes Pipeline drugs market?
The key molecule types in the Genital Herpes Pipeline drugs market are Small Molecule, Live Attenuated Vaccine, DNA Vaccine, Recombinant Vector Vaccine, Synthetic Peptide, mRNA Vaccine, Subunit Vaccine, Monoclonal Antibody, Vaccine.
-
What are the major companies in the Genital Herpes Pipeline drugs market?
The major companies in the Genital Herpes Pipeline drugs market are Rational Vaccines Inc, AiCuris Anti-infective Cures AG, NanoViricides Inc, Shulov Innovative Science Ltd, Abivax SA, AlphaVax Inc, Anteris Technologies Ltd, Astellas Pharma Inc, Auritec Pharmaceuticals Inc, Auro Vaccines LLC, and Biomere LLC among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.